StockMirror — Stock Screener

AKUMS Q4 FY26 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Akums reported a mixed FY26: a challenging H1 due to API price erosion and low domestic demand, but a strong H2 recovery driven by CDMO volume growth (+25%+ in H2) and record adjusted EBITDA (INR522 cr, +13.3% YoY). Q4 EBITDA margins improved to 13.1% (+420 bps YoY) on operating leverage. Key negatives: PAT declined to INR256 cr (vs INR344 cr) due to prior-year deferred tax benefit; API business continued losses (INR40 cr negative EBITDA); and no overall revenue guidance was provided. Positives: strong CDMO momentum, new contracts (Zambia $25M/year, European EUR200M), healthy cash position (INR1,682 cr), and expected sharp reduction in API losses. Management remains cautiously optimistic about FY27, with double-digit CDMO volume growth expected in H1 and margin expansion from new contracts in FY28. , , ,

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized organic growth (CDMO volume, new contracts, Zambia) while actively working on margin improvement through operating leverage, niche product mix, and cost rationalization in underperforming segments (trade generics, API). They also highlighted maintaining R&D investment for long-

About Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited (AKUMS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More